Loading clinical trials...
Loading clinical trials...
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of DNTH103 In Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
Conditions
Interventions
Claseprubart
Claseprubart
+1 more
Locations
158
United States
Clinical Study Site
Birmingham, Alabama, United States
Clinical Study Site
Phoenix, Arizona, United States
Clinical Study Site
Scottsdale, Arizona, United States
Clinical Study Site
Los Angeles, California, United States
Clinical Study Site
San Francisco, California, United States
Clinical Study Site
San Francisco, California, United States
Start Date
February 10, 2025
Primary Completion Date
December 31, 2028
Completion Date
December 31, 2030
Last Updated
April 21, 2026
NCT06290141
NCT06752356
NCT06920004
NCT07027111
NCT06637072
NCT07121985
Lead Sponsor
Dianthus Therapeutics
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions